NCT00345345View on ClinicalTrials.gov

Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 17, 2006

Primary Completion Date

August 1, 2017

Study Completion Date

October 27, 2020

Conditions
T-LGL Lymphoproliferative Disorders
Interventions
BIOLOGICAL

Alemtuzumab (Campath)

Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00345345 - Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia | Biotech Hunter | Biotech Hunter